Oncotarget Progress in Research and its role

Oncotarget assured its readers again that all scientific publications will always be available in PubMed, Scopus, Biological Abstracts, Web of Science, BIOSIS Previews and EMBASE. Through a co-operation with the National Library of Medicine, Oncotarget will achieve its aim of becoming the first research journal to submit a whole issue to PubMed few days after online publication.Oncotarget is a biomedical journal is peer-reviewed twice a week that covers research in all fields of oncology and publishes sub-units of on topics that are not related to oncology. These sub-sections include Immunology and Microbiology, Aging, Pathology, Autophagy, Chromosomes and many other areas.

From the time it was established in 2010, the journal has published seven volumes and 324 issues. Currently, the journal is in its eighth volume.In all the published works, the ethics that are recommended by the Committee on Publication must apply. Still, a direct object identifier (DOI) must be given to every publication that is made in the journal. Motivated by the need to solve the 21st challenges, Oncotarget’s mission is to strive to be a journal that is famous for the fast and extensive dissemination of valued biomedical studies. Ultimately, it is a journal that gets managed by scientists and its other for other scientists. It will continue to focus to be a resourceful tool so that it can help all the scientists with their contributions to the growth of science.

The journal seeks to apply clinical and basic medicine to treat, control and prevent diseases. Its aim is that people may live without suffering from any disease.Recently a journal from Oncotarget was published in Research Gate. The research sought to identify and validate any prognostic gene biomarkers to predict survival in patients who have acute myeloid leukemia. From the results, eleven genes significantly associated with the disease got identified. These genes can be used be as markers of the acute myeloid leukemia and proved to be suitable markers for predicting the survival of a suffering the disease. To carry out the study, the researcher screened the gene using a survival package.

Eric Lefkofsky’s Tempus to Provide Data For Breast Cancer Treatment

Breast Cancer is the most common form of Cancer in the world today. However, despite the high prevalence, there is little data to show the treatment patterns. This has forced the doctors to provide treatment without the benefit of genetic information.It is this challenge that the Tempus is seeking to address. The Company has partnered with the University of Chicago to provide the breast cancer specialists at the UChicago with molecular analysis. The data provided will help the doctors to provide personalized treatment to the patients.Eric Lefkofsky said that the Company would collect data from 1,000 patients who have breast cancer. The doctors will use the data to analyze the patterns of breast cancer and also how the patients respond to treatments.Tempus, founded in 2015 focuses on genomic sequencing which helps the doctors to provide personalized treatments.

About Eric Lefkofsky

Eric is the co-founder of the Chicago-based Company Tempus. He is also the Chief Executive Officer of the Company. Tempus is a technology Company that has developed systems to help treat cancer.In addition to Tempus, Eric has founded other Companies like Lightbank which is a Company that invests in disruptive technology. He is the co-founder of Groupon that is a global e-commerce marketplace. Eric is the co-founder of other successful companies:

  • ü Uptake Technologies:
  • ü Echo Global Logistics
  • ü InnerWorkings
  • ü Mediaocean

All these Companies are technology based.Eric is also involved in different philanthropic work. He established the Lefkofsky Family Foundation together with his wife. The Foundation is a private charitable foundation that provided initiatives to help improve the quality of life.He serves as a trustee of different organizations including Lurie Children’s Hospital, The Museum of Science and Industry, The Art Institute, and the World Business Chicago.Eric serves as a member of the Board of Trustees of the Steppenwolf Theatre Company. He attended the University of Michigan and later received his Juris Doctor Law from the same university.Eric is an adjunct professor at the University of Chicago. He has also published a book ‘Accelerated Disruption.’

Clay Siegall is a renowned cancer treatment specialist.

 

Seattle Genetics is earning attention, in the field of cancer treatment investigative research. The company CEO, who is also the company President, is Clay Siegall. Dr. Siegall co-founded the institute in 1998. His other responsibility, falls under being appointed, as the chairperson of the Seattle Genetics board committee. He is known for having a deep passion for helping to improve the lives of people, who suffer from cancer, since he began his vocation into biomedical research. Dr. Siegall is known by his peers, as a tireless worker, who has personally lead the institute, to a great many advances in the field of cancer studies, including, revolutionary treatments for cancer survivors.

After Dr. Siegall earned his Ph.D. from George Washington University, majoring in the field of Genetics, he accumulated a number of career accomplishments. When he started out, as a Senior Research Investigator, he worked at the Pharmaceutical Research Institute, owned by Bristol-Myers. He soon, earned a promotion to the status of Leading Scientist, until advancing in the ranks to Staff Fellow, as well as, Biotechnology Fellow, both at the National Cancer Institute. These accomplishments fueled his desire to found his own company, Seattle Genetics. Company stock prices have essentially tripled in value in only a 5 year period.

Dr. Siegall is known for his commitment to focusing on cancer research, while using only the most modern equipment. Seattle Genetics, is the first institute, to create antibody-drug conjugates, which earned them the FDA’s approval in 2011. With their recent expansion, they are able to assist cancer survivors, in over 60 countries. Dr. Siegall is renowned, for his leadership role in raising in excess of 1.2 billion dollars, for Seattle Genetics, from both private and public funding. This influx of revenue has helped to create new advances for treating cancer survivors, by using only the most cutting-edge technology.

Dr. Clay Siegall, earned the Alumnus of the Year award, for Natural Sciences and Math, from the University of Maryland in 2013. Dr. Siegall has made numerous contributions to the scientific community, such as, publishing new methods and treatments for cancer patients.